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Industry Sector(s): Healthcare, Pharmaceutical 
Product Category: Therapeutic antibody  
 
 
Opportunity Overview 
 
Emphymab™ Biotech was formed to develop and commercialize medical therapies that address serious lung 
diseases. The founders are scientists and clinicians at Indiana University School of Medicine. Emphymab’s  lead 
technology is based on a novel monoclonal antibody that inactivates a newly discovered pathway involved in lung 
diseases and, thereby, halts progressive loss of lung function associated with emphysema. This technology has the 
potential to address the huge unmet medical need of patients suffering from chronic obstructive pulmonary disease 
(COPD) with emphysema, which is the 3rd leading cause of death worldwide. 
 
Markets & Applications 
 
The US market is comprised of 4.3 million emphysema patients. 
 
Based on our preclinical data, a treatment regimen would consist of 6 total doses (2 doses/month for 3 months). The 
price per dose is predicted to be $800, which is based the on current costs to patients for therapeutic antibodies. 
Therefore, the total available US market is over $20 billion. 
 
Competitive Advantage/Value Propositions 
 
Novel therapeutic targets for emphysema, identified through studies of the mechanisms of disease-induced lung 
destruction, with pending U.S. patent and international patent applications 
 
Ongoing developmental activities,  including creation of a humanized monoclonal antibody, will be proposed in our 
subsequent SBIR phase II grant proposal, which will have a budget total of up to $1 million over a 2 year period to 
complete these and other development activities 
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Researcher Biographies 
 
Brian Johnstone, Ph.D.  
Dr. Johnstone, (EmphyMab founder), is currently an Associate Research Professor of Medicine at IU 
School of Medicine.  He is also the Preclinical Director for the Regenerative Medicine Center at the 
Richard Roudebush VA Medical Center and Director of the Center for Translational Sciences Institutes 
small animal model Cardiovascular Ischemia and Vasculogenesis Core. His academic research involves 
evaluating the mechanisms of action and translational potential of stem cell therapies for diseases 
characterized by vascular dysfunction. Dr. Johnstone is a founder of two other Indianapolis area start-up 
Biotech companies: one developing a small molecule drug for Lou Gehrig’s disease; the other developing 
biological factors derived from stem cells for multiple neurological diseases, including stroke.  
 
Previously he was an early employee of Sangamo BioSciences, located in the San Francisco Bay area. 
During Dr. Johnstone’s six years at Sangamo he was responsible for running the preclinical development 
program for their lead therapeutic compound for cardiovascular diseases. His area of expertise in drug 
development is preclinical development through IND submission and has involved many direct interactions 
with regulatory authorities. As an active member of EmphyMab, he is directing the early development of a 
monoclonal antibody for the first therapeutic target of Chronic Obstructive Pulmonary Disease (COPD) 
resulting from emphysema.  He is also engaged in strategic evaluation and selection of additional 
therapeutic indications as wells as establishing a pipeline of candidate molecular entities for addressing 
unmet medical needs in diseases of vascular inflammation and injury. 
 
Matthias Clauss, Ph.D. 
Dr. Clauss received his PhD from the University of Heidelberg and his postdoctoral training from the 
Columbia University in New York. He is Associate Research Professor of Cellular and Integrative 
Physiology and member of the Indiana Center for Vascular Biology and Medicine at IU School of 
Medicine. His research program analyzes mechanisms of endothelial cell activation and aims to identify the 
links between inflammation and angiogenesis. A specific focus is on the regulation of angiogenic (VEGF) 
and anti-angiogenic (EMAPII) factors and their receptor-mediated signaling. In an ongoing collaboration 
with Dr. Petrache, who was the first to demonstrate the link between endothelial cell death and emphysema, 
EMAPII neutralizing antibodies were established as therapeutic tools for treating cigarette smoke induced 
emphysema. As EMAPII both induces apoptosis and is released during this process, it is their central 
hypothesis that EMAPII is part of a self-sustaining machinery of destruction in the progression of lung 
emphysema induced by cigarette smoking. As founding member of EmphyMab, Matthias Clauss is poised 
to help bringing this antibody forward to clinical application in addition to further analyzing the mechanism 
of how this antibody interferes with the induction and progression of emphysema. 
 
Irina Petrache, M.D.  
Dr. Petrache is Professor of Medicine, Biochemistry, and Molecular Biology at the Indiana University. She 
is a physician scientist, board certified in Pulmonary and Critical Care Medicine, and principal investigator 
of a laboratory that studies mechanisms of lung injury and repair pertinent to cigarette smoke-induced 
chronic lung disease. The projects in the laboratory employ a translational approach, investigating 
intermolecular interactions, cell biology, animal models of disease, and human biological samples to 
answer questions related to the lung and systemic effects of cigarette smoking. The Petrache laboratory’s 
main goal is to identify targets of therapy and to quickly bring them to bedside to help individuals who 
suffer from COPD such as emphysema. This interest led to Emphymab, Inc, where Dr. Petrache is involved 
as a founding member and a contributor to research directions and clinical insight. 
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Development Plans/Needs 
 
1. Development and validation of a lead candidate high specificity, fully humanized EMAP II 
monoclonal antibody.  
 
2. Following attract substantial funding to continue non-clinical development as well as potentially 
perform early safety and proof-of-concept clinical trials.  
 
3. Explore opportunities to partner or out-license this program to a larger company possessing the 
necessary resources for late-stage development and commercialization. 
 
